Skip Navigation

Your Environment. Your Health.

Selected Publications

Environmental Innate Immunity Group

  1. Gowdy KM, Fessler MB. Emerging roles for cholesterol and lipoproteins in lung disease. Pulmonary pharmacology & therapeutics 2013 26(4):430-437. [Abstract (http://www.ncbi.nlm.nih.gov/pubmed/22706330?dopt=Abstract) ]

  2. Santos AJ, Meinecke M, Fessler MB, Holden DW, Boucrot E. Preferential invasion of mitotic cells by Salmonella reveals that cell surface cholesterol is maximal during metaphase. Journal of cell science 2013; 126(Pt. 14):2990-2996.  [Abstract (http://www.ncbi.nlm.nih.gov/pubmed/23687374?dopt=Abstract) ]

  3. Madenspacher JH, Azzam KM, Gowdy KM, Malcolm KC, Nick JA, Dixon D, Aloor JJ, Draper DW, Guardiola JJ, Shatz M, Menendez D, Lowe J, Lu J, Bushel P, Li L, Merrick BA, Resnick MA, Fessler MB. p53 Integrates host defense and cell fate during bacterial pneumonia.  Journal of Experimental Medicine 2013 210(5):891-904. [Abstract (http://www.ncbi.nlm.nih.gov/pubmed/23630228?dopt=Abstract) ]

  4. Jaramillo R, Cohn RD, Crockett PW, Gowdy KM, Zeldin DC, Fessler MB. Relation between objective measures of atopy and myocardial infarction in the United States. Journal of Allergy and Clinical Immunology 2013 131(2):405-411. [Abstract (http://www.ncbi.nlm.nih.gov/pubmed/22921873?dopt=Abstract) ]

  5. Palvinskaya T, Antkowiak M, Burg E, Lenox CC, Ubags N, Cramer A, Rincón M, Dixon AE, Fessler MB, Poynter ME, Suratt BT. Effects of acute and chronic low density lipoprotein exposure on neutrophil function. Pulmonary pharmacology & therapeutics 2013 26(4):405-411.  [Abstract (http://www.ncbi.nlm.nih.gov/pubmed/23084986?dopt=Abstract) ]

  6. Madenspacher JH , Azzam KM, Gong W, Gowdy KM, Vitek MP, Laskowitz DT, Remaley AT, Wang JM, Fessler MB. Apolipoproteins and apolipoprotein mimetic peptides modulate phagocyte trafficking through chemotactic activity. The Journal of biological chemistry 2012 287(52):43730-43740. [Abstract (http://www.ncbi.nlm.nih.gov/pubmed/23118226?dopt=Abstract) ]

  7. Jaramillo R, Cohn RD, Crockett PW, Gowdy KM, Zeldin DC, Fessler MB.. Relation between objective measures of atopy and myocardial infarction in the United States. J Allergy Clin Immunol. 2012; (Online 23 August 2012):doi:10.1016/j.jaci.2012.06.033. [Abstract (http://www.ncbi.nlm.nih.gov/pubmed/22921873) ]

  8. Smoak K, Madenspacher J, Jeyaseelan S, Williams B, Dixon D, Poch KR, Nick JA, Worthen GS, Fessler MB, Effects of liver X receptor agonist treatment on pulmonary inflammation and host defense.. Journal of immunology (Baltimore, Md. : 1950) 2008; 180(5):3305-3312. [Abstract] (http://www.ncbi.nlm.nih.gov/pubmed/18292555?dopt=Abstract) 

  9. Brass DM, Hollingsworth JW, Fessler MB, Savov JD, Maxwell AB, Whitehead GS, Burch LH, Schwartz DA, The IL-1 type 1 receptor is required for the development of LPS-induced airways disease. Journal of Allergy and Clinical Immunology 2007 Jul; 120(1):121-7. [Abstract] (http://www.ncbi.nlm.nih.gov/pubmed/17512577?dopt=Abstract) 

  10. Fessler MB, Arndt PG, Nick JA, Malcolm KC, Worthen GS, A Dual Role for RhoA in Suppression and Induction of Cytokines in the Human Neutrophil. Blood 2007; 109(3):1248-56.

  11. Jeyaseelan S, Young SK, Fessler MB, Liu Y, Malcolm KC, Yamamoto M, Akira S, and Worthen GS, TRIF-Mediated Signaling Contributes to Innate Immune Responses in the Lung During Escherichia coli Pneumonia. Journal of Immunology 2007; 78(5):3153-60.

  12. Cha SI, Fessler MB, Cool CD, King TE, Brown KK, Lymphoid Interstitial Pneumonia: Clinical Features, Associations, and Prognosis. European Respiratory Journal 2006; 28(2):364-9.

  13. Morimoto K, Janssen WJ, Fessler MB, McPhillips KA, Borges VM, Bowler RP, Xiao YQ, Kench JA, Henson PM, Vandivier RW, Lovastatin Enhances Clearance of Apoptotic Cells (Efferocytosis) with Implications for Chronic Obstructive Pulmonary Disease. Journal of Immunology 2006; 176(12):7657-65.

  14. Fessler MB, Young SK, Arndt PG, Walker T, Palic MR, Lieber JG, Jeyaseelan S, Nick JA, Worthen GS, A Role for HMG-CoA Reductase in Pulmonary Inflammation and Host Defense. American Journal of Respiratory and Critical Care Medicine 2005; 171:606-615.

  15. Arndt PG, Young SK, Lieber JG, Fessler MB, Nick JA, Worthen GS, Systemic inhibition of c-Jun-NH2-Terminal Kinase Decreases Pulmonary Neutrophil Recruitment and Modulates Actin Assembly after LPS Exposure. American Journal of Respiratory and Critical Care Medicine 2005; 171:978-986.

  16. Walker TS, Worthen GS, Poch KR, Lieber JG, Saavedra MT, Malcolm KC, Fessler MB, Vasil ML, Nick JA, Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infection & Immunity 2005; 73(6):3693-701.

  17. Arcaroli J, Fessler MB, Abraham E, Genetic Polymorphisms and Sepsis. Shock 2005; 24(4):300-12.

  18. Fessler MB, Arndt PG, Frasch SC, Lieber JG, Bratton DL, Malcolm KC, Worthen GS, Lipid Rafts Regulate Lipopolysaccharide-Induced Activation of Cdc42 and Inflammatory Functions of the Human Neutrophil. Journal of Biological Chemistry 2004; 279:39989 – 39998.

  19. Frasch SC, Henson PM, Nagaosa K, Fessler MB, Borregaard N, Bratton L, Phospholipid Flip-Flop and Phospholipid Scramblase (PLSCR 1) Co-localize to Uropod Rafts in fMLP Stimulated Neutrophils. Journal of Biological Chemistry 2004; 279:17625 – 17633.

  20. Fessler MB, Malcolm KC, Duncan MW, Worthen GS, New Experimental Approaches to the Signaling of Innate Immunity. American Journal of Respiratory Cell and Molecular Biology 2004; 31(Supp):S62-66.

  21. Fessler MB, Malcolm KC, Duncan MW, Worthen GS, A Genomic and Proteomic Analysis of Activation of the Human Neutrophil by Lipopolysaccharide and Its Mediation by p38 Mitogen-activated Protein Kinase. Journal of Biological Chemistry 2002; 277(35):31291-31302.

  22. Wang TJ, Mort EA, Nordberg P, Chang Y, Cadigan ME, Mylott L, Ananian LV, Thompson BT, Fessler M, Warren W, Wheeler A, Jordan M, Fifer MA, Utilization Management Intervention to Reduce Unnecessary Testing in the Coronary Care Unit. Archives of Internal Medicine 2002; 162(16):1885-90.

Back to Top